6.32
+0(+0.00%)
Currency In USD
| Previous Close | 6.32 |
| Open | 6.28 |
| Day High | 6.46 |
| Day Low | 6.21 |
| 52-Week High | 16.77 |
| 52-Week Low | 5.56 |
| Volume | 516,856 |
| Average Volume | 665,003 |
| Market Cap | 362.12M |
| PE | -2.77 |
| EPS | -2.28 |
| Moving Average 50 Days | 9.98 |
| Moving Average 200 Days | 11.33 |
| Change | 0 |
If you invested $1000 in Olema Pharmaceuticals, Inc. (OLMA) since IPO date, it would be worth $128.98 as of December 26, 2024 at a share price of $6.32. Whereas If you bought $1000 worth of Olema Pharmaceuticals, Inc. (OLMA) shares 3 years ago, it would be worth $656.28 as of December 26, 2024 at a share price of $6.32.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Olema Oncology Presents Updated Clinical Results for Palazestrant in Combination with Ribociclib at the San Antonio Breast Cancer Symposium
GlobeNewswire Inc.
Dec 10, 2024 12:00 PM GMT
Palazestrant, in combination with ribociclib, demonstrated promising clinical activity, a safety profile consistent with ribociclib and endocrine therapy, and favorable tolerability in patients with ER+/HER2- advanced or metastatic breast cancer With
Olema Oncology Announces FDA Clearance of Investigational New Drug Application for OP-3136, a Potent KAT6 Inhibitor
GlobeNewswire Inc.
Dec 09, 2024 12:00 PM GMT
Phase 1 clinical trial for OP-3136 to initiate in early 2025 SAN FRANCISCO, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discove
Olema Oncology Announces New Clinical Trial Collaboration and Supply Agreement with Novartis in Frontline Metastatic Breast Cancer as well as $250 Million Equity Private Placement
GlobeNewswire Inc.
Dec 02, 2024 12:00 PM GMT
Clinical trial collaboration and supply agreement enables pivotal Phase 3 OPERA-02 clinical trial of palazestrant in combination with ribociclib in frontline ER+/HER2- metastatic breast cancer; trial initiation expected in mid-2025$250.0 million equi